Discovery Accelerated

BioSymetrics is accelerating early stage drug discovery by building a more comprehensive view of human health and pharmaceutical research using AI.

BioSymetrics is impacting every stage of drug discovery and pharmaceutical research. Roll-over the hot spots below to see how.

TARGET-BASED DRUG DISCOVERY

Applying our ContingentAI framework to clinical data allows for novel gene-disease associations
Our in vivo experimental platform allows us to work in specific genetic contexts, allowing scalable complementation assays
Drug screening leverages our phenotypic barcoding platform, allowing automated lead identification for multi-dimensional phenotype rescue
Predicted off-target effects and toxicity models are used to optimize lead structures

Our target-based approach leverages computational and experimental processes to better predict in vivo efficacy and off-target effects.

PHENOTYPE-BASED DRUG DISCOVERY

Applying our Contingent-AI™ framework to clinical data allows for novel gene-disease associations
Our in vivo experimental platform allows us to work in specific genetic contexts, allowing scalable complementation assays
Drug screening leverages our phenotypic barcoding platform, allowing automated lead identification for multi-dimensional phenotype rescue
Predicted off-target effects and toxicity models are used to optimize lead structures

The Contingent-AI™ computational framework begins with phenotypic screens as input, and predicts molecular mechanism, shortening timelines for target/mechanism identification.

COMPUTATIONAL

Contingent A.I.™

  • Dynamically reduces bias from experimental datasets, including from high-content screening
  • Automated preprocessing of disparate data types (e.g. HCS, proteomics, genomics / transcriptomics) and data sources for faster discovery

EXPERIMENTAL

In Vivo Phenotypic Barcoding

  • We leverage a multi-dimensional “barcode” of in vivo phenotypic characteristics predictive of potential clinical applications and toxicity

AI DRUG DISCOVERY

BioSymetrics Combines Experimental and Machine Learning Methods to Enrich Target-Based Drug Discovery and Shorten Timelines for Phenotype-Based Drug Discovery

Life science companies tend focus on machine learning, ignoring the impact of the decisions they made in collecting and processing their data.

BioSymetrics has built a fundamentally different approach to Data Science, optimizing every step of the pharmaceutical research process using Contingent-AI™.

Pre-processing Artificial Intelligence

The result: less time spent in data processing, easier data integration, more accurate results for diagnostics and drug discovery, as well as truly autonomous capabilities for precision medicine

“Augusta Architect is unique in its focus on efficient pre-processing, enabling more transparent model building in biomedicine. We’re excited to be users of the platform.”

Dr. Eric SchadtFounder and CEO, Sema4

“Augusta has supported us in a variety of projects in different settings. In health insurance, BioSymetrics saved us months of man hours and approximately $6.4 million (£5-million) annually … the use of Augusta enabled the company to drive faster, more accurate and meaningful innovation.”

Matt HickeyFounder and CEO, Intacare
Recent Blog Posts
May 21, 2020 in Drug Discovery, Event

Mechanism of Action Prediction Platform – Webinar

Mechanism of Action Prediction Platform - Webinar
Read More
May 11, 2020 in Case Study, Drug Discovery

Poster Presentation: MIT 2020 AI for Drug Discovery Conference

Some of our high level learning was recently presented at the 2020 MIT AI for Drug Discovery conference in February. (more…)
Read More
May 4, 2020 in Article, Blog Post, Case Study, Media, Uncategorized

MOA Prediction Platform to Help With COVID-19 Research

BioSymetrics Mechanism of Action Prediction Platform framework will be put to work both in prioritizing chemical libraries and in predicting mechanism for identified compounds. Per the three COVID-19 research initiatives…
Read More
April 8, 2020 in Article, Drug Discovery, Media

MaRS: How Canadian Startups Are Tackling the COVID-19 Crisis

The MaRS community has been very welcoming to us.  We are honored to have been listed among these prestigious start-up companies working around the clock to address the COVID-19 crisis.…
Read More